Showing 941-950 of 1059 results for "".
- Blood-Based Biomarker Test Highly Effective At Identifying Those at Risk of Developing Parkinson Diseasehttps://practicalneurology.com/news/blood-based-biomarker-test-highly-effective-at-identifying-those-at-risk-of-developing-parkinson-disease/2470393/Study results published in JAMA Neurology demonstrated an association between elevated L1CAM-positive extracellular vesicle (L1EV) α-synuclein serum levels and the risk of developing Parkinson disease (PD) or related dementia. The retrospective, cross-sectional multicente
- Commercially Available Plasma p-tau217 Biomarker Immunoassay for Alzheimer Disease as Accurate as CSF Biomarker Testing According to New Studyhttps://practicalneurology.com/news/commercially-available-plasma-p-tau217-biomarker-test-for-alzheimer-disease-as-accurate-as-csf-biomarker-testing-according-to-new-study/2470388/Results of a study published in JAMA Neurology demonstrated the high diagnostic accuracy and consistency of a commercially available phosphorylated tau at threonine 217 (p-tau217) test (ALZpath, Carlsbad, CA) in identifying abnormal amyloid beta (Aβ) and tau concentrations associate
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- Combination Therapy More Effective than Aspirin Alone For Stroke Prevention According to INSPIRES Clinical Trialhttps://practicalneurology.com/news/combination-therapy-more-effective-than-aspirin-alone-for-stroke-prevention-according-to-inspires-clinical-trial/2470373/Combination therapy, consisting of clopidogrel with aspirin, initiated within 72 hours of stroke onset in people with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause, was associated with a lower risk of new stroke at 90 days compared to the use
- FDA Grants Orphan Drug Designation to AAV Gene Therapy Product for Malignant Gliomahttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-to-aav-gene-therapy-product-for-malignant-glioma/2470368/NXL-004 (NeuExcell Therapeutics, Philadelphia, PA) has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA). NXL-004 is the first investigational adeno-associated virus vector (AAV) gene therapy product developed as a potential treatment for malignant glioma to rec
- AMA Issues New Principles for AI Development, Deployment, and Usehttps://practicalneurology.com/news/ama-issues-new-principles-for-ai-development-deployment-and-use-2/2470352/The American Medical Association (AMA) announced the release of new principles for augmented intelligence (AI) development, deployment, and use. According to the AMA, these principles represent a critical step toward fostering a consistent governance structure for advancements in health care tech
- Gantenerumab Did Not Slow Cognitive Decline in People with Early Alzheimer Disease According to 2 Clinical Trial Resultshttps://practicalneurology.com/news/ganenterumab-did-not-slow-cognitive-decline-in-people-with-early-alzheimer-disease-according-to-2-clinical-trial-results/2470338/Treatment with the monoclonal antibody (mAb) gantenerumab (Genentech, South San Francisco, CA; Roche, Basel, Switzerland) was associated with a lower amyloid plaque burden in people with early Alzheimer disease (AD), but it did not slow cognitive decline after 116 weeks. These findings are from t
- FDA Fast Track Designation and IND Clearance Granted to Novel Gene Therapy for GRN-Related Frontotemporal Dementiahttps://practicalneurology.com/news/fda-fast-track-designation-and-ind-clearance-granted-to-novel-gene-therapy-for-grn-related-frontotemporal-dementia/2470333/The Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for AVB-101 (AviadoBio; London, United Kingdom), an adeno-associated virus (AAV) gene therapy developed as a potential treatment for people with frontotemporal dementia (FTD) with mutations in the progra
- Encouraging Safety Data for Investigational NTRX-07 Therapy for Alzheimer Disease Targeting Cannabinoid Type 2 Receptorhttps://practicalneurology.com/news/encouraging-safety-data-for-investigational-ntrx-07-therapy-for-alzheimer-disease-targeting-cannabinoid-type-2-receptor/2470329/In a phase 1b clinical trial, short-term treatment with NTRX-07 (NeuroTherapia, Cleveland, Ohio), an investigational small molecule targeting the cannabinoid type 2 (CB2) receptor, was associated with favorable pharmacokinetic and safety data in a small group of healthy volunteers and a subset of
- Study from CTAD 2023 Compares Sensitivity of 4 Blood-Based Biomarkers for Preclinical Alzheimer Diseasehttps://practicalneurology.com/news/study-from-ctad-2023-compares-sensitivity-of-4-blood-based-biomarkers-for-preclinical-alzheimer-disease/2470323/A study comparing the sensitivity of amyloid beta (Aβ) 40/42 ratio, plasma phosphorylated tau at threonine 181 (p-tau181), p-tau217, and neurofilament light chain (NfL) in low-risk (LR) versus high-risk (HR) cognitively healthy adults found that p-tau217 was associated with both high-risk fo